List view / Grid view
4 September 2015 | By Oxford Global
Production is now complete for the 2nd Annual Drug Discovery USA Congress taking place on the 29th & 30th of October 2015 in Boston, USA...
4 September 2015 | By Victoria White
Researchers have shown that combining immunotherapy with aspirin or other COX inhibitors substantially slowed bowel and melanoma skin cancer growth in mice...
4 September 2015 | By Victoria White
Researchers have successfully identified the exact composition of sea snake venom, which makes the future development of synthetic antivenoms more realistic...
4 September 2015 | By Victoria White
Researchers have identified a pathway that causes resistance to chemotherapy and radiation treatments and a new drug, KG5, that targets this pathway...
3 September 2015 | By Victoria White
The deals market for antisense RNAi therapeutics witnessed a record year in 2014, with a total value of almost $5.6 billion across 59 transactions...
3 September 2015 | By Victoria White
AmpliPhi Biosciences Corporation has announced that Alexander Gaidamaka has been appointed as the new Vice President of Chemistry, Manufacturing and Control...
3 September 2015 | By Victoria White
The University of Brighton has announced it is sharing in a €5.9m EU grant to support the development of a new treatment for chronic liver disease...
3 September 2015 | By Victoria White
Horizon and Redx have announced a new research collaboration to progress Redx’s pan-RAF inhibitor programme, for out-licensing in oncology indications...
2 September 2015 | By Victoria White
Nearly all advanced oesophageal cancers harbour genetic mutations that can be targeted with emerging drug therapies, according to a new study...
2 September 2015 | By Victoria White
ESCMID advocates the need for greater education, guidance and research on the build-up, treatment and prevention of biofilms...
2 September 2015 | By Victoria White
Novogen has confirmed its scientific review has identified high value opportunities for its technology platforms in areas of unmet patient need...
2 September 2015 | By Victoria White
In the Phase 1 study, subcutaneous administration of ALN-PCSsc resulted in an up to 83% lowering of LDL-C, with an up to 64 ± 5% mean maximum reduction, comparable to published results for anti-PCSK9 MAbs...
1 September 2015 | By Charlotte Batchelor
Bristol-Myers Squibb Company and QIMR Berghofer Medical Research Institute have signed a research collaboration and license agreement to discover novel therapeutic antibodies against an undisclosed immuno-oncology...
1 September 2015 | By Nick Jackson
Dr Koslowski brings over 15 years’ experience across biopharmaceutical research and development, specialising in drug target discovery and clinical validation...
28 August 2015 | By Victoria White
Researchers from University of Pittsburg have discovered the molecular mechanisms behind resilience to noise-induced tinnitus...
